Industry News

Interpretation of 2026 H1 Medical Aesthetics Market Data: Device-Numbered OEM Ushers in Structural Growth

Interpretation of 2026 H1 Medical Aesthetics Market Data: Device-Numbered OEM Ushers in Structural Growth

Market Overview: Continuous Scale Growth, Accelerating Structural Differentiation

In the first half of 2026, China's medical aesthetics market continued its growth trend, but the structure of growth is undergoing profound changes.

In terms of the light medical aesthetics market size, the proportion of non-surgical medical aesthetics services has reached 47.4%, an increase of about 5 percentage points compared with the same period last year. This data indicates that consumers are shifting from "drastic" plastic surgery to "gradual fine-tuning" light medical aesthetics projects.

Injection projects (hyaluronic acid, botulinum toxin, collagen injection, etc.) remain the main force of light medical aesthetics, but the growth rate has fallen from over 30% in 2023 to around 15-18%. Photoelectric projects (Thermage, Ultherapy, intense pulsed light, etc.) maintain growth of over 20%, becoming the fastest-growing segment in the light medical aesthetics field.

Consumer Changes: From "Visible Results" to "Anti-Aging"

The shift in consumer decision-making logic is the most notable feature of the market in the first half of the year.

Demand side: The demand for "short-term results" is being replaced by "long-term anti-aging." More and more consumers no longer pursue one-time drastic changes, but choose to maintain long-term condition through continuous skin management, injection supplementation, and daily care. This shift has a direct impact on the demand structure for upstream raw materials and products—market demand for ingredients with long-term nourishing effects such as recombinant collagen, peptide raw materials, and sodium hyaluronate continues to rise.

Decision side: Consumers have become more rational. "Check qualifications first, then price" has become the new decision-making order. Brands' registration certificates, OEM factories' qualifications, and product traceability information have all become content that consumers actively check before purchasing. This trend forces brands to display compliance qualifications and traceability information more in marketing.

Channel side: The proportion of online channels has further increased, but content formats are changing. Traditional seeding notes and before-and-after comparisons are decreasing, replaced by popular science, ingredient analysis, and qualification interpretation content. Consumers no longer readily trust "seeding" but are more willing to believe professional interpretations supported by data and scientific evidence.

Supply-Side Changes: Accelerated Compliance

The major change on the supply side in the first half of the year is the accelerated advancement of compliance.

Product registration level: In the first half of 2026, the number of medical aesthetics medical device registration certificates newly approved by NMPA increased by about 20% year-on-year, among which recombinant collagen and sodium hyaluronate categories accounted for a relatively high proportion. This indicates that leading enterprises are accelerating the layout of compliant products.

Production level: The release of the draft for comments on the new version of GMP has put forward higher requirements for the production management system of OEM enterprises. Requirements such as full-chain UDI traceability, sterilization process validation, and entrusted production audits are eliminating a batch of small and medium-sized OEM enterprises with extensive management, and industry concentration is further increasing.

Brand level: More and more brands are beginning to value deep binding with compliant OEM factories. OEM enterprises with rich registration certificate reserves, complete quality systems, and large-scale production capacity have stronger bargaining power in order negotiations.

Where Are the Opportunities for OEM Enterprises

Based on the changing trends in market data in the first half of the year, OEM enterprises have clear structural opportunities in the following directions:

First, recombinant collagen products. Whether injection products or dressing/gel products, recombinant collagen is currently the raw material direction with the fastest growth and high market attention. OEM enterprises with independent fermentation platforms and freeze-drying capacity have first-mover advantages in this track.

Second, post-photoelectric repair products. The continuous growth of photoelectric projects has directly driven demand for post-operative repair products. Products such as medical dressings, repair gels, and cold spray repair liquids are standard equipment for post-operative care after photoelectric projects.

Third, combined oral + topical solutions. Consumers' demand for anti-aging is shifting from single topical use to internal regulation and external nourishment. If OEM enterprises can provide combined solutions of "oral nutritional supplementation + topical repair products," they will be more competitive.

Fourth, compliance capability premium. Against the backdrop of accelerated compliance, the "compliance capability" of OEM enterprises with complete registration certificate systems and quality management systems is itself a scarce resource. Brands are willing to pay a premium for compliance because they cannot afford the cost of violations.

The Logic Behind the Data

The number 47.4% is not just a statistical result; it represents an underlying logic transformation that the entire medical aesthetics industry is undergoing—from "plastic surgery" to "management," from "surgery" to "maintenance," and from "one-time consumption" to "continuous consumption."

The impact of this logic transformation on upstream enterprises is profound. It means longer product life cycles, higher repurchase rates, and stronger customer stickiness, while also meaning higher requirements for quality, safety, and compliance.

For OEM enterprises like Weitai Group, which has done medical aesthetics efficacy skincare for 25 years, possesses full-category production capacity, and has more than 110 Class II medical device registration filings, this trend is favorable. Because the more standardized the industry and the more rational consumers become, the more advantages truly capable enterprises will have.

Second Half Outlook

Looking ahead to the second half of 2026, three key factors deserve close attention from OEM enterprises:

First, the implementation of the new regulations on new raw material filing (July 15). This will directly affect the selection of raw materials used in formulas and product registration strategies.

Second, the conclusion of the transition period for classification adjustments. The classification upgrade of categories such as radiofrequency therapeutic devices will officially take effect at the end of the year, and the registration and market landscape of related products will face reshaping.

Third, the normalization of supervision over medical aesthetics advertising. The follow-up effects of the joint rectification by 14 ministries and commissions will be directly reflected in the marketing budget allocation of brands, and demand for popular science and compliance content will continue to grow.

The superposition of these three factors will jointly push the medical aesthetics industry into a new stage of "compliance-driven, quality is king."

Data sources: National Medical Products Administration registration data, public medical aesthetics industry reports, industry white papers from platforms such as SoYoung/Meibei


About Weitai Group | OEM/ODM Contract Manufacturing Services

Weitai Group was founded in 2012, has done medical aesthetics efficacy skincare for 25 years, and is a medical aesthetics skincare OEM/ODM contract manufacturer with many years in the industry. Its four factories (Guangzhou, Hunan, Zhaoqing) cover a total area of over 150,000 ㎡, with 50+ fully automatic production lines, holding more than 110 Class II medical device registration filings, and accumulating a mature formula library + mature formulas, with 72 patents.

Core contract manufacturing capabilities:

  • Medical dressings/masks (daily output of 1 million pieces, Class II medical device certificate)
  • Freeze-dried powder (daily output of 1 million pairs, developed by its own R&D laboratory)
  • Essence serums/toners, lotions, creams (full category of cosmetic product number)
  • Medical gels/hemostatic materials (Class II medical device certificate)

Quality assurance: US GMPC + EU ISO22716 dual certification, 38 quality inspections, yield rate 99.99%. Has served hundreds of brands (including Chando, etc.).

Cooperation models: OEM processing with supplied materials | ODM private label customization | Shitaqi spot direct supply

Delivery capability: Regular 7-15 days, expedited 3-day shipment. Official website: www.weitaigd.com

← Back to News
Call Us
📞

Weitai Support

● Online
微肽智能客服

Hello, I'm Weitai Group's AI assistant

  • 25 years of OEM/ODM experience
  • 25 years of OEM/ODM experience
  • Extensive formula library
  • 110+ Class II device registrations

How can I help you?

WeChat QR Code

👆 Scan to add WeChat

WeChat ID: weitai-bioWeChat Consultation

Business Inquiry · Quotation · Partnership

➊
点击右上角「···」
选择「发送给朋友」
或「分享到朋友圈」

分享到微信

QR Code

请用微信扫描二维码